KMT2A and chronic myelogenous leukemia, BCR-ABL1 positive: AML (Shanmugam et al., 2017), CML, ALL (Billot et al., 2011), APL (Nishioka et al., 2010), MLL, MM (Audia and Campbell, 2016; Kalinkova et al., 2023), HL (Zhang and Zhang, 2020)